IceCure Medical Future Growth
Future criteria checks 2/6
IceCure Medical is forecast to grow earnings and revenue by 47.4% and 52% per annum respectively while EPS is expected to grow by 56% per annum.
Key information
47.4%
Earnings growth rate
55.98%
EPS growth rate
| Medical Equipment earnings growth | 17.3% |
| Revenue growth rate | 52.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Aug 2026 |
Recent future growth updates
Recent updates
ICCM: U.S. Breast Cancer Authorization And Install Base Expansion Will Drive Upside
Analysts have revised their fair value estimate for IceCure Medical from about $30.00 to $10.00, citing updates to key model inputs such as the discount rate, revenue growth assumptions, profit margin and future P/E expectations. What's in the News for IceCure Medical IceCure Medical received U.S. Food and Drug Administration marketing authorization in October 2025 for its ProSense system in the local treatment of low-risk breast cancer in women aged 70 and above who receive adjuvant endocrine therapy, including patients who are not eligible for surgery.ICCM: Expanding Global Cryoablation Adoption Will Drive Future Upside Potential
Analysts have updated their price target on IceCure Medical to $30.00, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their valuation models. What’s in the News for IceCure Medical IceCure Medical expanded its United States sales and marketing teams, adding dedicated personnel in territories including New York, Southern California and the Midwest, along with extra clinical support to help train sites and support adoption of the ProSense system for breast cancer cryoablation.
ICCM: Legal Overhang And Nasdaq Compliance Efforts Will Shape Upside Potential
Analysts now value IceCure Medical at an updated fair value of $31.50 per share, up from $2.45, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples that have significantly increased their price target framework. What's in the News for IceCure Medical IceCure Medical received a Tel Aviv District Court decision approving the certification of a shareholder class action related to a 2021 private placement, with the company stating it believes the claims are without merit and that it intends to defend itself vigorously.
ICCM: Japanese Breast Cancer Opportunity Will Drive Future Upside Potential
Analysts have updated their price target for IceCure Medical from $3.13 to $30.50, citing revised assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. What's in the News for IceCure Medical IceCure Medical highlighted a new peer-reviewed article in the International Journal of Surgery comparing cryoablation with radiofrequency ablation for early-stage breast cancer, ahead of its participation in the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto, Japan, on June 25-27, 2026.FDA Breast Cancer Clearance And Reimbursement Progress Will Transform Long Term Cryoablation Adoption
Catalysts About IceCure Medical IceCure Medical develops and commercializes the ProSense cryoablation system for minimally invasive treatment of tumors, including low risk early breast cancer. What are the underlying business or industry changes driving this perspective?Regulatory And Reimbursement Delays Will Challenge Breast Cancer Adoption Yet Long Term Potential Will Build
Catalysts About IceCure Medical IceCure Medical develops and commercializes the ProSense cryoablation system for minimally invasive treatment of breast cancer and other tumors. What are the underlying business or industry changes driving this perspective?Shareholders May Find It Hard To Justify Increasing IceCure Medical Ltd's (NASDAQ:ICCM) CEO Compensation For Now
Key Insights IceCure Medical to hold its Annual General Meeting on 20th of August Total pay for CEO Eyal Shamir...Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 22 | -11 | -10 | -10 | 2 |
| 12/31/2027 | 9 | -16 | -14 | -13 | 3 |
| 12/31/2026 | 4 | -18 | -11 | -11 | 2 |
| 6/30/2026 | 4 | -17 | -16 | -16 | N/A |
| 3/31/2026 | 4 | -16 | -15 | -15 | N/A |
| 12/31/2025 | 3 | -15 | -15 | -15 | N/A |
| 9/30/2025 | 3 | -15 | -14 | -14 | N/A |
| 6/30/2025 | 3 | -16 | -14 | -14 | N/A |
| 3/31/2025 | 3 | -15 | -14 | -14 | N/A |
| 12/31/2024 | 3 | -15 | -13 | -13 | N/A |
| 9/30/2024 | 4 | -14 | -11 | -11 | N/A |
| 6/30/2024 | 3 | -14 | -11 | -11 | N/A |
| 3/31/2024 | 3 | -14 | -13 | -12 | N/A |
| 12/31/2023 | 3 | -15 | -13 | -13 | N/A |
| 9/30/2023 | 3 | -16 | -15 | -14 | N/A |
| 6/30/2023 | 3 | -16 | -15 | -14 | N/A |
| 3/31/2023 | 3 | -16 | -15 | -14 | N/A |
| 12/31/2022 | 3 | -17 | -15 | -14 | N/A |
| 9/30/2022 | 4 | -16 | -17 | -16 | N/A |
| 6/30/2022 | 4 | -15 | -17 | -16 | N/A |
| 3/31/2022 | 3 | -13 | -14 | -14 | N/A |
| 12/31/2021 | 4 | -10 | -13 | -13 | N/A |
| 9/30/2021 | 4 | -8 | -9 | -8 | N/A |
| 6/30/2021 | 4 | -6 | -7 | -6 | N/A |
| 3/31/2021 | 4 | -4 | -5 | -5 | N/A |
| 12/31/2020 | 4 | -4 | -4 | -4 | N/A |
| 9/30/2020 | 3 | -4 | -2 | -2 | N/A |
| 6/30/2020 | 3 | -4 | -1 | 0 | N/A |
| 3/31/2020 | 2 | -4 | N/A | -1 | N/A |
| 12/31/2019 | 2 | -5 | N/A | -2 | N/A |
| 9/30/2019 | 1 | -5 | N/A | N/A | N/A |
| 6/30/2019 | 1 | -4 | N/A | -4 | N/A |
| 3/31/2019 | 1 | -4 | N/A | -4 | N/A |
| 12/31/2018 | 1 | -4 | N/A | -3 | N/A |
| 9/30/2018 | 1 | -3 | N/A | N/A | N/A |
| 6/30/2018 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2018 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2016 | 1 | -3 | N/A | -3 | N/A |
| 9/30/2016 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2016 | 1 | -4 | N/A | -4 | N/A |
| 3/31/2016 | 1 | -4 | N/A | -3 | N/A |
| 12/31/2015 | 1 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 1 | -4 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICCM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ICCM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ICCM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ICCM's revenue (52% per year) is forecast to grow faster than the US market (12.9% per year).
High Growth Revenue: ICCM's revenue (52% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICCM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 06:15 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IceCure Medical Ltd is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Anthony Vendetti | Maxim Group |